This is a multicenter, neither you nor the study doctors know who gets the real treatment, Long-Term Extension (LTE) study to measure the long-term safety and how well it works of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period.
Official registry: https://clinicaltrials.gov/study/NCT07003425 · Apogee Therapeutics, Inc. · enrollment listed as 350
Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are APG777, APG777, or APG777. The registry lists allocation as randomized. This is a multicenter, neither you nor the study doctors know who gets the real treatment, Long-Term Extension (LTE) study to measure the long-term safety and how well it works of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948).
They plan to enroll about 350 people at 74 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777
Interventions: APG777, APG777, APG777
Primary outcome (registry wording): Number of Participants with Treatment Emergent Adverse Events
ABBVIE CALL CENTER
abbvieclinicaltrials@abbvie.com
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
+ 51 sites outside the US on the same record
This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.
NCT00177268 · Official ClinicalTrials.gov record · University of Pittsburgh
This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze healthy human skin and how the these microorganisms might change in patients with atopic dermatitis (AD), a skin condition also known as eczema.
NCT00605878 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)
Background: \- Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S.
NCT01631617 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary